Emmaus Life Sciences returns to profit in Q2 FY26; revenue more than doubles to $6.3 million vs Q2 FY25
EMMA•Quarterly results
Emmaus Life Sciences swung to net income of $1.3 million in Q2 2026 from a net loss a year earlier.
Net revenues more than doubled to $6.3 million, up 124% year over year.
Drivers of revenue and expenses
Results included $4.8 million of revenue from an upfront fee and royalties under the NeoImmuneTech license agreement.
Other expense climbed 81% to $2.5 million, while selling expense fell 27% to $0.5 million.
Liquidity and going-concern warning
Cash and cash equivalents totaled $2.8 million at June 30, 2026, with management citing substantial doubt about going concern.
